RxDoctor Payments DataLook up a doctor →

Pankit Vachhani, MD

Hematology & Oncology · Birmingham, ALNPI 1982968764

Payments from drug & device makers

$7,895,426in general payments, 2019–2025

Across 2,198 payments — averaging $3592.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.6M
  • Incyte Corporation$1.3M
  • Takeda Pharmaceuticals U.S.A., Inc.$1.3M
  • Blueprint Medicines Corporation$636K
  • AbbVie$444K
  • Karyopharm Therapeutics Inc.$423K
  • plus $2.1M from 36 others
$11,969in research payments, 2019–2025

Across 12 payments — averaging $997.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$11K
  • Amgen$854
  • Pfizer$330
  • GSK$104

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,895,426 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$42,801
Medicare patients
148
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →